Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1978 ARTÍCULOS , VIENDO DEL 391 AL 405

Senotherapeutics: Targeting senescent cells for the main age-related diseases

Boccardi V, Mecocci P.

Mech Ageing Dev. 2021 Jul;197:111526. doi: 10.1016/j.mad.2021.111526. Epub 2021 Jun 21.

Rationale, study design and implementation of the LUCINDA Trial: Leuprolide plus Cholinesterase Inhibition to reduce Neurologic Decline in Alzheimer's

Butler T, Goldberg JD, Galvin JE, Maloney T, Ravdin L, Glodzik L, de Leon MJ, Hochman T, Bowen RL, Atwood CS.

Contemp Clin Trials. 2021 Aug;107:106488. doi: 10.1016/j.cct.2021.106488. Epub 2021 Jun 22.

Targeting Common Signaling Pathways for the Treatment of Stroke and Alzheimer's: a Comprehensive Review

Eskandari S, Sajadimajd S, Alaei L, Soheilikhah Z, Derakhshankhah H, Bahrami G.

Neurotox Res. 2021 Oct;39(5):1589-1612. doi: 10.1007/s12640-021-00381-7. Epub 2021 Jun 25.

O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer's disease and related tauopathies: analysis of the patent literature

Bartolomé-Nebreda JM, Trabanco AA, Velter AI, Buijnsters P.

Expert Opin Ther Pat. 2021 Dec;31(12):1117-1154. doi: 10.1080/13543776.2021.1947242. Epub 2021 Jul 8.

Immune Response in Neurological Pathology: Emerging Role of Central and Peripheral Immune Crosstalk

Passaro AP, Lebos AL, Yao Y, Stice SL.

Front Immunol. 2021 Jun 10;12:676621. doi: 10.3389/fimmu.2021.676621. eCollection 2021.

Pharmacological relevance of CDK inhibitors in Alzheimer's disease

Malhotra N, Gupta R, Kumar P.

Neurochem Int. 2021 Sep;148:105115. doi: 10.1016/j.neuint.2021.105115. Epub 2021 Jun 25.

A carte blanche approval in Alzheimer's

Nat Biotechnol. 2021 Jul;39(7):781. doi: 10.1038/s41587-021-00995-4.

Tau and TDP-43 synergy: a novel therapeutic target for sporadic late-onset Alzheimer's disease

Latimer CS, Liachko NF.

Geroscience. 2021 Aug;43(4):1627-1634. doi: 10.1007/s11357-021-00407-0. Epub 2021 Jun 29.

Cell competition from development to neurodegeneration

Costa-Rodrigues C, Couceiro J, Moreno E.

Dis Model Mech. 2021 Jul 1;14(7):dmm048926. doi: 10.1242/dmm.048926. Epub 2021 Jun 30.

Filling the void for new Alzheimer's disease therapy

Nat Aging. 2021 Jul;1(7):567-568. doi: 10.1038/s43587-021-00092-w.

Repurposing bromocriptine for Aβ metabolism in Alzheimer's disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer's disease with presenilin 1 (PSEN1) mutations

Kondo T, Banno H, Okunomiya T, Amino Y, Endo K, Nakakura A, Uozumi R, Kinoshita A, Tada H, Morita S, Ishikawa H, Shindo A, Yasuda K, Taruno Y, Maki T, Suehiro T, Mori K, Ikeda M, Fujita K, Izumi Y, Kanemaru K, Ishii K, Shigenobu K, Kutoku Y, Sunada Y, Kawakatsu S, Shiota S, Watanabe T, Uchikawa O, Takahashi R, Tomimoto H, Inoue H.

BMJ Open. 2021 Jun 30;11(6):e051343. doi: 10.1136/bmjopen-2021-051343.

Aluminum environmental pollution: the silent killer

Alasfar RH, Isaifan RJ.

Environ Sci Pollut Res Int. 2021 Sep;28(33):44587-44597. doi: 10.1007/s11356-021-14700-0. Epub 2021 Jul 1.

Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression

Tolar M, Hey J, Power A, Abushakra S.

Int J Mol Sci. 2021 Jun 14;22(12):6355. doi: 10.3390/ijms22126355.

Vitamin K2 Holds Promise for Alzheimer's Prevention and Treatment

Popescu A, German M.

Nutrients. 2021 Jun 27;13(7):2206. doi: 10.3390/nu13072206.

Peptides Derived from Growth Factors to Treat Alzheimer's Disease

Gascon S, Jann J, Langlois-Blais C, Plourde M, Lavoie C, Faucheux N.

Int J Mol Sci. 2021 Jun 4;22(11):6071. doi: 10.3390/ijms22116071.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias